Simcere Pharmaceutical Group Announces Resignation of an Independent Director
Published: Oct 12, 2012
NANJING, China, Oct. 12, 2012 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the resignation of Mr. Gary Siu Kwan Sik, an independent director of the Company, effective from October 11, 2012. Mr. Sik resigned for health and personal reasons. Mr. Sik has confirmed that he has no disagreement with the Company or any other board members. The Company appreciates the service that Mr. Sik has provided to the Company. Simcere is actively recruiting a replacement for Mr. Sik.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Jie Liu D'Elia
Simcere Pharmaceutical Group
In the United States:
Brunswick Group LLC
In Hong Kong:
Joseph Lo Chi-Lun
SOURCE Simcere Pharmaceutical Group